Literature DB >> 14514783

Audit of the clinical usefulness of a rapid qualitative ELISA screen for antimyeloperoxidase and antiproteinase 3 antibodies in the assessment of patients with suspected vasculitis.

A Aslam1, T L Newman, S A Misbah.   

Abstract

BACKGROUND: The need for urgent antineutrophil cytoplasmic antibody (ANCA) results when assessing patients with acute renal failure, pulmonary renal syndrome, or mononeuritis multiplex has led to the development of a rapid qualitative ELISA screening assay for antibodies to myeloperoxidase (MPO) and proteinase 3 (PR3). AIMS: To report the use of a rapid qualitative ELISA screen for PR3-ANCA and MPO-ANCA in a regional immunology laboratory and its correlation with standard indirect immunofluorescence (IIF) and quantitative ELISA for PR3-ANCA and MPO-ANCA.
METHODS: Over 12 months, 103 samples requiring urgent ANCA testing were screened by a rapid qualitative ELISA and the results compared with IIF and quantitative ELISA assays for PR3-ANCA and MPO-ANCA.
RESULTS: There was an excellent correlation between the rapid qualitative ELISA and standard ANCA IIF and a routine ELISA for MPO/PR3-ANCA, with sensitivities ranging from 82% to 100%. There were two false negatives, which gave weak to moderately positive values as determined by routine ELISA. However, the clinical relevance of these two cases is doubtful.
CONCLUSIONS: The rapid ELISA for anti-MPO and anti-PR3 correlates well with quantitative ELISA and IIF ANCA, and urgent management decisions in patients with suspected small vessel vasculitis can be based with confidence on this test.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14514783      PMCID: PMC1770077          DOI: 10.1136/jcp.56.10.775

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  5 in total

1.  Test characteristics of immunofluorescence and ELISA tests in 856 consecutive patients with possible ANCA-associated conditions.

Authors:  J H Stone; M Talor; J Stebbing; M L Uhlfelder; N R Rose; K A Carson; D B Hellmann; C L Burek
Journal:  Arthritis Care Res       Date:  2000-12

2.  Rapid screening assay for anti-GBM antibody and ANCAs; an important tool for the differential diagnosis of pulmonary renal syndromes.

Authors:  K W Westman; P G Bygren; I Eilert; A Wiik; J Wieslander
Journal:  Nephrol Dial Transplant       Date:  1997-09       Impact factor: 5.992

Review 3.  International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA)

Authors:  J Savige; D Gillis; E Benson; D Davies; V Esnault; R J Falk; E C Hagen; D Jayne; J C Jennette; B Paspaliaris; W Pollock; C Pusey; C O Savage; R Silvestrini; F van der Woude; J Wieslander; A Wiik
Journal:  Am J Clin Pathol       Date:  1999-04       Impact factor: 2.493

Review 4.  Antiproteinase 3- and antimyeloperoxidase-associated vasculitis.

Authors:  C F Franssen; C A Stegeman; C G Kallenberg; R O Gans; P E De Jong; S J Hoorntje; J W Tervaert
Journal:  Kidney Int       Date:  2000-06       Impact factor: 10.612

Review 5.  Antineutrophil cytoplasmic antibodies and associated diseases: a review of the clinical and laboratory features.

Authors:  J Savige; D Davies; R J Falk; J C Jennette; A Wiik
Journal:  Kidney Int       Date:  2000-03       Impact factor: 10.612

  5 in total
  1 in total

1.  Emergency testing for antineutrophil cytoplasmic antibodies combined with a dialog-based policy between clinician and biologist: effectiveness for the diagnosis of ANCA-associated vasculitis.

Authors:  Johnny Sayegh; Caroline Poli; Alain Chevailler; Jean-François Subra; François Beloncle; Pierre Antoine Deguigne; Céline Beauvillain; Jean-François Augusto
Journal:  Intern Emerg Med       Date:  2014-10-25       Impact factor: 3.397

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.